Eldoquin Forte 4%
Generic Name
Topical Preparations
Each gram of cream contains:
Hydroquinone...............40 g
Skin bleaching cream
Topical application of hydroquinone provides a reversible depigmentation of the skin by inhibition of enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of bleached areas.
Eldoquin Forte 4% cream is indicated for the gradual bleaching of hyperpigmented skin conditions such as cholasma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation.
The cream is intended for night-time use only since it contains no sunblocking agents. For daytime usage, Solaquin Forte or Eldopaque Forte should be prescribed.
Eldoquin Forte 4% is contraindicated in case of prior hypersensitivity or allergic reaction to hydroquinone or any of the other ingredients.
Prior history of sensitivity or allergic reactions to this product or any of its ingredients.
Drug Interactions
Side Effects/Adverse Effects
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued and the physician notified immediately.
Pregnancy & Lactation
Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used in pregnant women only when clearly indicated.


It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Dosage & Administration
Eldoquin Forte 4% cream should be applied to affected area and rubbed in well twice daily or as directed by the physician to achieve maximum therapeutic potential.
The preparation is intended to be used during night hours as the product contains no sun blocking agent.
There is no recommended dosage for children under 12 years of age, except under the advice and supervision of a physician.
There have been no systemic reactions from the use of topical hydroquinone in Eldoquin Forte 4% cream. However, treatment should be limited to relatively small areas of the body at any one time, since some patients experience a transiet reddening of the skin anda mild burning sensation which does not preclude treatment.
Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.
Patients should test for skin sensitivity before using Eldoquin Forte 4% by applying a small amount to an unbroken patch of skin and check in 24 hours. Minor redness is not a contraindication, by where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. Close patient supervision is recommended. Contact with the eyes should be avoided. If no bleaching or lightening effect is noted after 2 months of treatment, the medication should be discontinued.
There ar eno sunblocking or sunscreening agents in Eldoquin Forte 4% and since minimal sunlight exposure may reverse the bleaching effect of this prepration, it should be used only at night or on areas of the body covered by protective clothing. During daytime, sunblocking or broad spectrum sunscreen preparations or protective clothing should be used to prevent the bleached areas from repigmentation. For the daytime bleaching of unwatned pigmented areas, the use of Solaquin Forte or Eldopaque Forte should be considered.
This preparation contains sodium metabisulphite, a sulfite that may cause serious allergic-type reactions (e.g. hives, itching, wheezing, anaphylaxis, serious asthma attacks) in certain susceptible persons).
Store at 25°C.
Tube of 14.2 or 28.4 grams.
ICN Pharmaceuticals
Date Added/Updated
11th October 2012 1:47 pm


Share This!

Respected Sites

Need Help?

on-call support